HR Execs on the Move

NCS PHARMACEUTICALS

www.ncspharma.com

 
NCS PHARMACEUTICALS is a Somerset, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

U.S. Dermatology Partners

We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.

Groupe Essaim

Groupe Essaim Inc. is a Boucherville, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

ReactDx

Ambulatory Cardiac Monitoring | Mobile Cardiac Telemetry, Holter, Extended Holter & Wireless Event | Implantable Monitoring Service | Helping physicians add quality years to patients lives, ONE patient at a time.

Nestle Health Science

At Nestlé Health Science, we’re advancing nutritional therapy to change the approach of managing your health. Behind our pioneering company are people who are driving breakthroughs and innovating for impact. Here, you have the chance to change the course of health and your career. Our people are exploring new territory and breaking new ground in areas such as GI, critical care, surgery, oncology, healthy ageing, food allergy, obesity, brain health and pediatrics. They are changing the way doctors think about meeting the nutritional needs of patients, and the way patients and consumers manage their own health. They know the faces, hear the stories and celebrate the successes of people who had their lives transformed thanks to Nestlé Health Science solutions. Be part of a journey that changes the course of health.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)